AMPH (Amphastar Pharmaceuticals Inc.) stock: $23.62, $1.00B market cap, $290.1M cash, $1.33B EV, $1.36B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
AMP-019
Stage not disclosed · Active Modality: intranasal epinephrine nasal spray
Indications- Emergency treatment of allergic reactions including anaphylaxis (Stage not disclosed)
Status note Prescription product candidate; filing does not state current development stage.
AMP-105
Stage not disclosed · Active Modality: peptide
Partnerships Hanxin / Anji: peptide proprietary product candidates licensed (economics not disclosed)
Indications- Multiple poorly treated cancers (Stage not disclosed)
Status note Described as a first-in-class peptide targeting a novel mechanism to modulate cell growth and metastasis.
AMP-107
Stage not disclosed · Active Modality: topical eye drop peptide
Target VEGFR (vascular endothelial growth factor receptor)
Partnerships Hanxin / Anji: peptide proprietary product candidates licensed (economics not disclosed)
Indications- Wet age-related macular degeneration (wet AMD) (Stage not disclosed)
Status note Described as the first non-injectable anti-VEGFR peptide, an alternative to routine eye injections.
AMP-109
Stage not disclosed · Active Modality: peptide-docetaxel conjugate
Partnerships Hanxin / Anji: peptide proprietary product candidates licensed (economics not disclosed)
Indications- Cancer (taxane-eligible) (Stage not disclosed)
Status note Designed to improve selectivity/bioavailability of docetaxel and reduce docetaxel-induced toxicity.
AMP-110
Stage not disclosed · Active Modality: synthetic human corticotropin (ACTH) analog peptide
Partnerships Hanxin / Anji: peptide proprietary product candidates licensed (economics not disclosed)
Status note Will target multiple indications per filing.
AMP-004
Stage not disclosed · Active Modality: biosimilar (interchangeable)
Aliases Insulin Aspart
Status note Interchangeable insulin product candidate; filing does not state whether this is the insulin candidate currently on file with the FDA.
AMP-005
Stage not disclosed · Active Modality: biosimilar (interchangeable)
Aliases Recombinant Human Insulin
Status note Interchangeable insulin product candidate.
AMP-028
Stage not disclosed · Active Modality: biosimilar
Status note Biosimilar outside the insulin portfolio; product identity not disclosed. API manufactured at the Eragny-sur-Epte, France facility.
BAQSIMI
Approved · Active Modality: nasal powder
Aliases glucagon nasal powder
Indications- Severe hypoglycemia (Approved)
Status note Approved branded product acquired from Eli Lilly in June 2023; transition services completed January 1, 2025.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.